Abstract
Objective: High rate of resistance to lamivudine is a major problem in treating chronic hepatitis B (CHB) patients. We investigated the course of virologic breakthrough (VB) after emergence of YMDD mutants in CHB patients receiving lamivudine. Methods: Ninety-three consecutive HBeAg-positive CHB patients treated with lamivudine (100 mg/day) who developed YMDD mutants and VB were enrolled. The clinical breakthrough (CB) was defined by elevation of alanine aminotransferase (ALT) >2 times the upper limit of normal. Results: The median age was 47 years, and genotype of hepatitis B virus (HBV) was all C. The median duration of lamivudine administration was 39 months, and median pre-lamivudine ALT and HBV DNA were 165 IU/l and 1.2 × 108 copies/ml. In all patients, CB concurred with VB or appeared some months following VB. When patients were divided into two groups according to time sequence of two breakthroughs - group 1 (VB followed by CB, n = 68) and group 2 (concurrent VB and CB, n = 25) - there was no difference in patient and virologic characteristics between the two groups. The median time from VB to CB was 8 months in group 1. Conclusion: VB might eventually progress to CB in HBeAg-positive patients harboring YMDD mutants with high pretreatment ALT and HBV DNA.
| Original language | English |
|---|---|
| Pages (from-to) | 293-298 |
| Number of pages | 6 |
| Journal | Intervirology |
| Volume | 51 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2008 Nov 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Virology
- Infectious Diseases
Cite this
}
Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B. / Kim, Do Young; Ahn, Sang Hoon; Lee, Hyun Woong; Park, Jun Yong; Kim, Seung Up; Paik, Yong Han; Lee, Kwan Sik; Han, Kwang Hyub; Chon, Chae Yoon.
In: Intervirology, Vol. 51, No. 4, 01.11.2008, p. 293-298.Research output: Contribution to journal › Article
TY - JOUR
T1 - Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B
AU - Kim, Do Young
AU - Ahn, Sang Hoon
AU - Lee, Hyun Woong
AU - Park, Jun Yong
AU - Kim, Seung Up
AU - Paik, Yong Han
AU - Lee, Kwan Sik
AU - Han, Kwang Hyub
AU - Chon, Chae Yoon
PY - 2008/11/1
Y1 - 2008/11/1
N2 - Objective: High rate of resistance to lamivudine is a major problem in treating chronic hepatitis B (CHB) patients. We investigated the course of virologic breakthrough (VB) after emergence of YMDD mutants in CHB patients receiving lamivudine. Methods: Ninety-three consecutive HBeAg-positive CHB patients treated with lamivudine (100 mg/day) who developed YMDD mutants and VB were enrolled. The clinical breakthrough (CB) was defined by elevation of alanine aminotransferase (ALT) >2 times the upper limit of normal. Results: The median age was 47 years, and genotype of hepatitis B virus (HBV) was all C. The median duration of lamivudine administration was 39 months, and median pre-lamivudine ALT and HBV DNA were 165 IU/l and 1.2 × 108 copies/ml. In all patients, CB concurred with VB or appeared some months following VB. When patients were divided into two groups according to time sequence of two breakthroughs - group 1 (VB followed by CB, n = 68) and group 2 (concurrent VB and CB, n = 25) - there was no difference in patient and virologic characteristics between the two groups. The median time from VB to CB was 8 months in group 1. Conclusion: VB might eventually progress to CB in HBeAg-positive patients harboring YMDD mutants with high pretreatment ALT and HBV DNA.
AB - Objective: High rate of resistance to lamivudine is a major problem in treating chronic hepatitis B (CHB) patients. We investigated the course of virologic breakthrough (VB) after emergence of YMDD mutants in CHB patients receiving lamivudine. Methods: Ninety-three consecutive HBeAg-positive CHB patients treated with lamivudine (100 mg/day) who developed YMDD mutants and VB were enrolled. The clinical breakthrough (CB) was defined by elevation of alanine aminotransferase (ALT) >2 times the upper limit of normal. Results: The median age was 47 years, and genotype of hepatitis B virus (HBV) was all C. The median duration of lamivudine administration was 39 months, and median pre-lamivudine ALT and HBV DNA were 165 IU/l and 1.2 × 108 copies/ml. In all patients, CB concurred with VB or appeared some months following VB. When patients were divided into two groups according to time sequence of two breakthroughs - group 1 (VB followed by CB, n = 68) and group 2 (concurrent VB and CB, n = 25) - there was no difference in patient and virologic characteristics between the two groups. The median time from VB to CB was 8 months in group 1. Conclusion: VB might eventually progress to CB in HBeAg-positive patients harboring YMDD mutants with high pretreatment ALT and HBV DNA.
UR - http://www.scopus.com/inward/record.url?scp=55649118675&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55649118675&partnerID=8YFLogxK
U2 - 10.1159/000170904
DO - 10.1159/000170904
M3 - Article
C2 - 19001828
AN - SCOPUS:55649118675
VL - 51
SP - 293
EP - 298
JO - Intervirology
JF - Intervirology
SN - 0300-5526
IS - 4
ER -